{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["givastomig"],["givastomig","nivolumab","chemotherapy"],["givastomig","chemotherapy"]],"indication":"advanced or metastatic solid tumors","name":"NCT04900818","nct_id":"NCT04900818","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04900818. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Dose Escalation: TJ033721 will be administered at up to 8 dose levels (0.1, 0.3, 1, 3, 5, 8, 12 and 15 mg/kg) bi weekly (Q2W) and 1 dose level (18 mg/kg) every 3 weeks (Q3W)\n\nDuring dose expansion, TJ033721 will be administered Q2W, starting at the RP2D or MTD in dose escalation.","label":"TJ033721 (givastomig)","type":"EXPERIMENTAL"},{"description":"TJ033721 will be administered in combination with nivolumab and chemotherapy","label":"TJ033721 (givastomig) in combination with nivolumab and chemotherapy","type":"EXPERIMENTAL"},{"description":"TJ033721 (givastomig) will be administered in combination chemotherapy","label":"TJ033721 (givastomig) in combination chemotherapy","type":"EXPERIMENTAL"},{"description":"TJ033721 (givastomig) will be administered in combination with durvalumab and chemotherapy","label":"TJ033721 (givastomig) in combination with durvalumab and chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Solid Tumor","Advanced Cancer","Metastatic Cancer","Gastric Cancer","Gastroesophageal Junction Carcinoma","Esophageal Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancer (BTC)"],"enrollment":{"count":330,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"TJ033721 (givastomig)","otherNames":[],"type":"DRUG"},{"name":"TJ033721 (givastomig) , nivolumab, chemotherapy","otherNames":[],"type":"DRUG"},{"name":"TJ033721 (givastomig), chemotherapy","otherNames":[],"type":"DRUG"},{"name":"TJ033721 (givastomig), durvalumab, chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-05","lead_sponsor":"I-Mab Biopharma US Limited","official_title":"A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose-limiting toxicities (DLTs)","timeFrame":"28 days"},{"measure":"Incidence and severity of AEs","timeFrame":"Up to 100 days post last dose"},{"measure":"Maximum tolerated or administered dose (MTD, MAD)","timeFrame":"28 Days"}],"references":[],"start_date":{"date":"2021-06-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04900818"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04900818"}